Chad M. Vezina

Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture.

DNA adduct formation in precision-cut rat liver and lung slices exposed to benzo[a]pyrene.

Subchronic exposure to TCDD, PeCDF, PCB126, and PCB153: effect on hepatic gene expression.

Hepatic gene downregulation following acute and subchronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Noggin is required for normal lobe patterning and ductal budding in the mouse prostate.

Retinoic acid induces prostatic bud formation.

Hedgehog signaling in prostate growth and benign prostate hyperplasia.

Dioxin causes ventral prostate agenesis by disrupting dorsoventral patterning in developing mouse prostate.

WNT5A selectively inhibits mouse ventral prostate development.

AHR signaling in prostate growth, morphogenesis, and disease.

Estrogen signaling is not required for prostatic bud patterning or for its disruption by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

beta-Catenin promotes respiratory progenitor identity in mouse foregut.

2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits fibroblast growth factor 10-induced prostatic bud formation in mouse urogenital sinus.

Androgenic regulation of ventral epithelial bud number and pattern in mouse urogenital sinus.

Isoform distinct time-, dose-, and castration-dependent alterations in flavin-containing monooxygenase expression in mouse liver after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment.

Sulfatase 1 is an inhibitor of ductal morphogenesis with sexually dimorphic expression in the urogenital sinus.

Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands.

Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.

A high-resolution molecular atlas of the fetal mouse lower urogenital tract.

Atlas of Wnt and R-spondin gene expression in the developing male mouse lower urogenital tract.

Patterns of Gene Expression in the Bovine Corpus Luteum Following Repeated Intra-Uterine Infusions of Low Doses of Prostaglandin F2alpha.